Brief: VBL Presents Data That Show The Potential Of Its Novel Anti-Mospd2 Monoclonal Antibodies For Multiple Sclerosis
11/09/2020 13:11
Sept 11 (Reuters) - Vascular Biogenics Ltd VBLT.O :
* VBL PRESENTS HUMAN PROOF-OF-CONCEPT DATA THAT SHOW THE
POTENTIAL
OF ITS NOVEL ANTI-MOSPD2 MONOCLONAL ANTIBODIES FOR MULTIPLE
SCLEROSIS AT THE MS VIRTUAL 2020 MEETING
Source text for Eikon: ID:nGNXqtPjf
Further company coverage: VBLT.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Notable Labs
See all newsUS STOCKS-Wall St ends sharply lower following Trump's anti-Powell tirade
US STOCKS-Wall St ends sharply lower amid Trump's tirade against Fed's Powell
US STOCKS-Wall St tumbles as Trump ramps up tirade against Fed's Powell
Brief: Notable Labs Says Co, Units Filed Voluntary Petition Under Provisions Of Chapter 7 Of Title 11 Of US Bankruptcy Code
Brief: Notable Labs Approved A Streamlined Operating Plan Which Includes Exploring Strategic Alternatives